Literature DB >> 18201267

Association of Epstein-Barr virus antibody levels with precancerous gastric lesions in a high-risk cohort.

Aaron J Schetter1, Wei-cheng You, Evelyne T Lennette, Mitchell T Gail, Charles S Rabkin.   

Abstract

We evaluated associations between Epstein-Barr virus (EBV) antibody levels and precancerous gastric lesions (chronic atrophic gastritis, intestinal metaplasia, and dysplasia) in 183 subjects from Linqu, China. Immunoglobulin G antibody titers to EBV nuclear antigen (EBNA) and viral capsid antigen (VCA) were determined by two-fold serial dilution using immunofluorescence assays. Histological progression and regression were assessed by gastroscopic examination at the time of phlebotomy and at follow up 2 years later. Antibody titers did not differ significantly among histological diagnoses determined at the time of phlebotomy. However, subjects with dysplasia at follow up had significantly higher geometric mean antibody titers for both anti-VCA and anti-EBNA. Subjects with greater than median antibody levels were more likely to progress between examinations, especially in the subgroup with intestinal metaplasia at the time of phlebotomy (odds ratios [95% confidence intervals]: 5.7 [1.6-20] for anti-EBNA >or=1:320; 3.8 [1.0-15] for anti-VCA >or=1:640). Our findings suggest a possible role for EBV reactivation at an early phase of gastric carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18201267     DOI: 10.1111/j.1349-7006.2007.00668.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  17 in total

1.  An ELISA method to compute endpoint titers to Epstein-Barr virus and cytomegalovirus: application to population-based studies.

Authors:  Raymond P Stowe; R Jeanne Ruiz; Christopher P Fagundes; Robin H Stowe; Min Chen; Ronald Glaser
Journal:  J Immunol Methods       Date:  2014-05-22       Impact factor: 2.303

2.  Divergent trends for gastric cancer incidence by anatomical subsite in US adults.

Authors:  M Constanza Camargo; William F Anderson; Jessica B King; Pelayo Correa; Cheryll C Thomas; Philip S Rosenberg; Christie R Eheman; Charles S Rabkin
Journal:  Gut       Date:  2011-05-25       Impact factor: 23.059

3.  Epstein-Barr virus infection in patients with chronic gastritis without Helicobacter pylori infection.

Authors:  Nevra Dursun; Ezgi Hacıhasanoğlu; Oğuzhan Okçu; Esra Paşaoğlu; Cem Leblebici
Journal:  Turk J Gastroenterol       Date:  2020-03       Impact factor: 1.852

4.  Case-case comparison of smoking and alcohol risk associations with Epstein-Barr virus-positive gastric cancer.

Authors:  M Constanza Camargo; Chihaya Koriyama; Keitaro Matsuo; Woo-Ho Kim; Roberto Herrera-Goepfert; Linda M Liao; Jun Yu; Gabriel Carrasquilla; Joseph J Y Sung; Isabel Alvarado-Cabrero; Jolanta Lissowska; Fernando Meneses-Gonzalez; Yashushi Yatabe; Ti Ding; Nan Hu; Philip R Taylor; Douglas R Morgan; Margaret L Gulley; Javier Torres; Suminori Akiba; Charles S Rabkin
Journal:  Int J Cancer       Date:  2013-08-28       Impact factor: 7.396

5.  Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis.

Authors:  M C Camargo; G Murphy; C Koriyama; R M Pfeiffer; W H Kim; R Herrera-Goepfert; A H Corvalan; E Carrascal; A Abdirad; M Anwar; Z Hao; J Kattoor; E Yoshiwara-Wakabayashi; Y Eizuru; C S Rabkin; S Akiba
Journal:  Br J Cancer       Date:  2011-06-07       Impact factor: 7.640

6.  Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis.

Authors:  M Constanza Camargo; Woo-Ho Kim; Anna Maria Chiaravalli; Kyoung-Mee Kim; Alejandro H Corvalan; Keitaro Matsuo; Jun Yu; Joseph J Y Sung; Roberto Herrera-Goepfert; Fernando Meneses-Gonzalez; Yuko Kijima; Shoji Natsugoe; Linda M Liao; Jolanta Lissowska; Sung Kim; Nan Hu; Carlos A Gonzalez; Yashushi Yatabe; Chihaya Koriyama; Stephen M Hewitt; Suminori Akiba; Margaret L Gulley; Philip R Taylor; Charles S Rabkin
Journal:  Gut       Date:  2013-04-12       Impact factor: 23.059

Review 7.  Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature.

Authors:  Anna E Coghill; Allan Hildesheim
Journal:  Am J Epidemiol       Date:  2014-08-28       Impact factor: 4.897

8.  Circulating Antibodies against Epstein-Barr Virus (EBV) and p53 in EBV-Positive and -Negative Gastric Cancer.

Authors:  M Constanza Camargo; Kyoung-Mee Kim; Keitaro Matsuo; Javier Torres; Linda M Liao; Douglas Morgan; Angelika Michel; Tim Waterboer; Minkyo Song; Margaret L Gulley; Ricardo L Dominguez; Yasushi Yatabe; Sung Kim; Gustavo Cortes-Martinez; Jolanta Lissowska; Jovanny Zabaleta; Michael Pawlita; Charles S Rabkin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-11-12       Impact factor: 4.254

9.  Use of Non-steroidal Anti-inflammatory Drugs for Chemoprevention of Inflammation-induced Prostate Cancer.

Authors:  Bilge Debeleç Bütüner; Mert Burak Öztürk
Journal:  Turk J Pharm Sci       Date:  2017-11-20

Review 10.  Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma.

Authors:  Margaret L Gulley
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.